Biontech presents encouraging phase 1/2 follow-up data for car-t candidate bnt211 in hard-to-treat solid tumors at esmo

Mainz, germany, september 9, 2022 – biontech se (nasdaq: bntx, “biontech” or “the company”) today presented positive follow-up data from its ongoing first-in-human phase 1/2 trial evaluating the safety and efficacy of the company's novel car-t cell therapy candidate, bnt211, in patients with relapsed or refractory advanced solid tumors. the results demonstrated encouraging signs of anti-tumor activity and the safety profile remained manageable for the two tested dose levels. the data were presented in the investigational immunotherapy proffered paper session at the european society for medical oncology (esmo) congress 2022 by prof. andreas mackensen, m.d., university hospital erlangen, germany.
BNTX Ratings Summary
BNTX Quant Ranking